Dr.Weifeng Yang

Director of product service department of Beijing Vitalstar Biotechnology Co., LTD., Doctor of clinical veterinary medicine of Northwest A&F University, postdoctoral fellow of life sciences of Peking University, engaged in research and development of small molecule induced pluripotent stem cells and genetically modified animal models. Currently, I am responsible for the research and development of liver disease models, including hepatitis B, NASH/MASH and liver cancer models, pharmacological and pharmacodynamic experiments, and NMPA on-site verification of new drugs. According to different etiologies of liver fibrosis, such as hepatic toxic injury (NASH/MASH, HBV/HCV, ASH, etc.) and cholestatic injury, the corresponding preclinical rodent  models were optimized. Including: (1) Hu-URG® mouse population screening, determination of human primary hepatocyte viability and optimization of hepatocyte transplantation process of mice with controllable liver injury humanized liver, achieving a human liver chimerism rate of up to 95% and a reconstruction success rate of up to 100%. (2) The first HBV-Tg transgenic mice with high expression of hepatitis B virology index in China had serum HBV-DNA of 10⁷~10⁸ IU/mL and HBsAg of 10⁴ IU/mL. (3) Diet induced DIO and MASH models; gene humanized MASH and liver humanized MASH models. (4) Humanized MASH-HCC models that are more closely related to human clinical complex disease characteristics:① Hu-URG®/ NPG-MASH-HCC model; ②HBV-MASH-HCC model. Papers from participating projects have been published in journals such as Cell, Science, Cell stem cell, and Stem cells.